Biocon initiates Phase III study for oral insulin
11 November 2009
Anju Ghangurde
Please Login to read the full article.
11 November 2009
Anju Ghangurde
aghangurde@yahoo.com
The Indian biotechnology company, Biocon, expects to report Phase III data on its oral insulin (IN-105) by June next year.
IN-105 is a novel analogue of insulin and uses a proprietary polymer technology acquired by Biocon from Nobex of the US, which allows modification of the drug structure...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Generex, Amarantus in collaboration to treat pre-diabetes
- 2011 Scrip Asia 100 - Flexibility the key to riding Asia's emerging giants
- Positive Phase III data for LifeCycle's 'improved Prograf' despite higher drop-out
- Biocon divests German arm AxiCorp for $58 million following Pfizer deal
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
